Pioneer Solution to Inflammatory Skin Diseases
We address autoimmune inflammatory skin conditions, such as psoriasis, with innovative solutions.
About
I Derm Pharma is a biotechnology company focused on developing a first-in-class Oral therapy, for treating autoimmune inflammatory skin diseases such as Psoriasis.
About 2-3% of the global population suffers from Psoriasis, a chronic and painful skin disease that significantly affects quality of life. Current treatment options for moderate-to-mild cases, such as oral therapies and biologics, have limitations: oral therapies often have limited efficacy and safety, while biologics are costly and may have long-term side effects. This highlights the need for new, safe, effective, and affordable oral treatments with better tolerability.
Our Solution
At I Derm Pharma, we have developed a proprietary small molecule therapy that introduces a first-in-class mechanism of action. This groundbreaking approach targets a novel pathway within the local skin's inflammatory pathway, effectively modulating inflammation without compromising the immune system. Our oral solution combines enhanced safety, low toxicity with high efficacy, offering the convenience of oral administration to address challenges associated with biologic injections.
Our Team
Dr. Sharon Navon
Co-founder & CEO
Dr. Navon is a chemist with more than 8 years of experience in managing building & leading large pharmaceutical R&D teams. She was the manager of the new peptide-active pharmaceutical ingredients development teams, responsible for the processes, the analytical package development, and successful implementation at production sites to achieve GMP lots.
Dr. Ofer Sarig
Co-founder
Dr. Sarig is the Head of the Laboratory of Molecular Dermatology as part of the Division of Dermatology at the Tel Aviv Sourasky Medical Center. Dr. Sarig contributes significantly to the field of dermatology research.
Prof. Eli Sprecher
Co-founder
Prof. Sprecher is the CEO of Tel Aviv Sourasky Medical Center. He is Frederick Reiss Professor of Dermatology at the Sackler Medical School, Tel Aviv University. Additionally, he serves as a section editor for the British Journal of Dermatology and is a board member of The European Society for Dermatological Research, along with being a member of the National Israeli Academy for Medical Sciences.
Zohar Gendler
Board Chairman